30
Participants
Start Date
January 10, 2018
Primary Completion Date
August 31, 2019
Study Completion Date
August 28, 2020
Voriconazole genotype-specific dosing
"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
Standard of Care
Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
Toronto General Hospital, Toronto
Princess Margaret Cancer Care Centre, Toronto
University Health Network, Toronto
OTHER